Figure 2From: Transplantation of genetically engineered cardiac fibroblasts producing recombinant human erythropoietin to repair the infarcted myocardiumPhotomicrographs of heart sections, immunostained with anti-human erythropoietin antibodies (brown), 4 weeks after cell transplantation. (A) Human kidney positive control. (B) saline-injected heart. (C) Non-transduced fibroblast-transplanted heart. (D) RhEPO in transduced fibroblast-transplanted heart (infarct zone). Arrows show rhEPO expression.Back to article page